Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | S100B | P04271 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.45 |
| ▸ | PGR | P06401 | 2/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3826223 | 0.87 | NPC1 (0.60) | PRF1NPC1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL7636169 | 0.84 | PRF1 (0.68) | PRF1NPC1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3939499 | 0.82 | NPC1 (0.58) | PRF1NPC1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL7970252 | 0.80 | NPC1 (0.53) | PRF1NPC1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL7979559 | 0.80 | ROCK2 (0.54) | PRF1NPC1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL1466724 | 0.79 | MAPT (0.58) | PRF1NPC1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3029409 | 0.78 | MAPT (0.55) | PRF1NPC1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL7780577 | 0.77 | PRF1 (0.51) | PRF1NPC1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL12634064 | 0.77 | NPC1 (0.50) | PRF1NPC1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL1407977 | 0.77 | MAPT (0.56) | PRF1NPC1ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
| EP-1140886-B1 | METHOD FOR THE PREPARATION OF 5-CYANOPHTHALIDE | LUNDBECK & CO AS H (DK) | 2003-04-02 | — | — | EP | disclosed |
| US-6392060-B2 | DEHYRATION OF THE CORRESPONDING 5-CARBOXYPHTHALIDE | H. LUNDBECK A/S (DK) | 2002-05-21 | — | — | US | disclosed |
| US-6392060-B1 | — | — | 2002-05-21 | — | — | US | disclosed |
| US-20020019546-A1 | Method for the preparation of 5-cyanophthalide | H. LUNDBECK A/S (DK) | 2002-02-14 | — | — | US | disclosed |
| EP-1140886-A1 | METHOD FOR THE PREPARATION OF 5-CYANOPHTHALIDE | H. LUNDBECK A/S (DK) | 2001-10-10 | — | — | EP | disclosed |
| EP-1015416-B1 | METHOD FOR THE PREPARATION OF CITALOPRAM | LUNDBECK & CO AS H (DK) | 2001-09-19 | — | — | EP | disclosed |
| US-6229026-B1 | REACTING AN ISOBENZOFURAN DERIVATIVE WITH GRIGNARD REAGENTS 4-HALOGEN-FLUOROPHENYL AND 3-HALOGEN-N,N-DIMETHYLPROPYLAMINE; CAUSING RING-CLOSURE OF THE PRODUCT AND CONVERSION TO 5-CYANO DERIVATIVE | H. LUNDBECK, A/S (DK) | 2001-05-08 | — | — | US | disclosed |
| WO-2000039112-A1 | METHOD FOR THE PREPARATION OF 5-CYANOPHTHALIDE | H. LUNDBECK A/S (DK) | 2000-07-06 | — | — | WO | disclosed |
| EP-1015416-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2000-07-05 | — | — | EP | disclosed |
| WO-1998019513-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | PRF1 4335/4885NPC1 3291/4885ALDH1A1 2016/4885 |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | CTH, CBS, SLC7A11 | PRF1 4221/4885NPC1 3258/4885ALDH1A1 2382/4885 |
| US-20020019546-A1 | Method for the preparation of 5-cyanophthalide | SLC6A4, TPH1, CPS1 | PRF1 3419/4885NPC1 1549/4885ALDH1A1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.